Skip To Main Content

Transplantační medicína

Nejnovější trendy

Prozkoumejte nejčtenější články a videa na Campus Sanofi

Seřadit
Rol inmunológico

Rol inmunológico

Esta infografía proporciona una visión detallada de por qué todos los lactantes menores de 12 meses están en mayor riesgo de enfermedad severa por VSR, basándose en los mecanismos inmunológicos subyacentes.

VESTIGE Trial Results: Dupilumab in Type 2 Asthma

VESTIGE Trial Results: Dupilumab in Type 2 Asthma

This video presents results from the Phase 4 VESTIGE trial, demonstrating how dupilumab improves airway structure and function in severe type 2 asthma. Using breakthrough Functional Respiratory Imaging technology, the study reveals structural improvements that conventional lung function tests may not detect.

VESTIGE Trial Results: Dupilumab in Type 2 Asthma

VESTIGE Trial Results: Dupilumab in Type 2 Asthma

This video presents results from the Phase 4 VESTIGE trial, demonstrating how dupilumab improves airway structure and function in severe type 2 asthma. Using breakthrough Functional Respiratory Imaging technology, the study reveals structural improvements that conventional lung function tests may not detect.

VESTIGE Trial Results: Dupilumab in Type 2 Asthma

VESTIGE Trial Results: Dupilumab in Type 2 Asthma

This video presents results from the Phase 4 VESTIGE trial, demonstrating how dupilumab improves airway structure and function in severe type 2 asthma. Using breakthrough Functional Respiratory Imaging technology, the study reveals structural improvements that conventional lung function tests may not detect.

VESTIGE Trial Results: Dupilumab in Type 2 Asthma

VESTIGE Trial Results: Dupilumab in Type 2 Asthma

This video presents results from the Phase 4 VESTIGE trial, demonstrating how dupilumab improves airway structure and function in severe type 2 asthma. Using breakthrough Functional Respiratory Imaging technology, the study reveals structural improvements that conventional lung function tests may not detect.

VESTIGE Trial Results: Dupilumab in Type 2 Asthma

VESTIGE Trial Results: Dupilumab in Type 2 Asthma

This video presents results from the Phase 4 VESTIGE trial, demonstrating how dupilumab improves airway structure and function in severe type 2 asthma. Using breakthrough Functional Respiratory Imaging technology, the study reveals structural improvements that conventional lung function tests may not detect.

VESTIGE Trial Results: Dupilumab in Type 2 Asthma

VESTIGE Trial Results: Dupilumab in Type 2 Asthma

This video presents results from the Phase 4 VESTIGE trial, demonstrating how dupilumab improves airway structure and function in severe type 2 asthma. Using breakthrough Functional Respiratory Imaging technology, the study reveals structural improvements that conventional lung function tests may not detect.

Så skyddar vi våra minsta: sammanfattning från webbinariet om Beyfortus

Så skyddar vi våra minsta: sammanfattning från webbinariet om Beyfortus

Praluent - mortalitní data

Praluent - mortalitní data

RSV Prevention for Every Infant: Favourable Safety Profile

RSV Prevention for Every Infant: Favourable Safety Profile

RSV is the primary cause of LRTIs in children worldwide.2 Infants aged 3 months old have the highest risk of severe RSV LRTIs.2 

Understanding RSV: Disease Burden and Nirsevimab’s Efficacy

Understanding RSV: Disease Burden and Nirsevimab’s Efficacy

In Singapore, RSV circulates all-year round and causes significant paediatric health and economic burden.2 This highlights the need and importance of RSV immunisation to reduce the burden of disease.2

Diagnosztikai Minijáték: Gaucher-kór

Diagnosztikai Minijáték: Gaucher-kór